RET基因在肿瘤中的研究现状和展望

doi:10.11904/j.issn.1002-3070.2015.05.018

实用肿瘤学杂志 ›› 2015, Vol. 29 ›› Issue (5): 467-470.doi: 10.11904/j.issn.1002-3070.2015.05.018

RET基因在肿瘤中的研究现状和展望

孙冀, 苗素生, 裴荣综述, 毛雄辉审校

哈尔滨医科大学附属肿瘤医院头颈外科(哈尔滨 150081)

收稿日期:2015-01-25 出版日期:2015-10-28 发布日期:2015-10-30
通讯作者: 毛雄辉,E-mail:15714642@qq.com
作者简介:孙冀,男,(1963-),博士,主任医师,从事头颈部肿瘤外科治疗的研究
基金资助:
哈尔滨市科委青年攻关基金资助项目(2006RFQX086)

Research of RET in cancer:Current and future

SUN Ji, MIAO Susheng, PEI Rong, MAO Xionghui

Department of Head and Neck surgery,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China

Received:2015-01-25 Online:2015-10-28 Published:2015-10-30

摘要/Abstract

摘要： 本文采用文献回顾的方法,对RET(Rearranged during transfection)原癌基因及编码产物的结构,参与细胞内信号的转导方式,以及RET基因与甲状腺癌、乳腺癌、肺癌关系的研究进展做一综述。RET基因编码酪氨酸激酶受体,参与细胞内信号转导,RET原癌基因重排在乳头状甲状腺癌中较常见,其在乳腺癌、肺癌中的重排研究近来受到关注。此外,RET也是肿瘤治疗的一个有意义的靶点。

关键词: RET, 甲状腺癌, 乳腺癌, 肺癌

Abstract: To review recent studies on the research advance of RET(Rearranged during transfection)oncogene in thyroid cancer,breast cancer,and lung cancer.The literatures on the structure of RET gene and coding product,cell signal transduction,relationship among thyroid cancer,breast cancer,and lung cancer are reviewed.RET gene encoding tyrosine kinase receptor,involving in cell signal transduction,rearrangement of RET gene is frequently seen in thyroid cancer,which is reported more and more in breast cancer,and lung cancer.Rearrangement of RET gene is closely correlated with the occurrence and progress of thyroid cancer,breast cancer,and lung cancer.Taking together,these findings suggest that RET present an attractive therapeutic target for the treatment of certain cancer subsets.

Key words: RET, Thyroid cancer, Breast cancer, Lung cancer

中图分类号:

R73-31

孙冀, 苗素生, 裴荣综述, 毛雄辉审校. RET基因在肿瘤中的研究现状和展望[J]. 实用肿瘤学杂志, 2015, 29(5): 467-470.

SUN Ji, MIAO Susheng, PEI Rong, MAO Xionghui. Research of RET in cancer:Current and future[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 467-470.

参考文献

1 Takahashi M,Ritz J,Cooper GM.Activation of a novel human transforming gene ret by DNA rearrangement[J].Cell,1985,42(2):581-588.
2 Pasini B,Hofstra RM,Yin L,et al.The physical map of the human RET proto-oncogene[J].Oncogene,1995,11(9):1737-1741.
3 Daniela Califano D,Rizzo CD,Alessio A,et al.Signaling through Ras is essential for Ret oncogene-induced cell differentiation in PCI2 cells[J].J Biol Chem,2000,275(25):19297-19305.
4 Mai KT,Lanary DC,Thomas J,et al.Ret oncogene protein expression in papillary thyroid carcinoma and related lesions[J].Tumor,2001,87(3):166-172.
5 Besset V,Scott RP,Ibanez CF,et al.Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase[J].J Biol Chem,2000,275(50):39159-39164.
6 Plaza-Menacho I,Burzynski GM,de Groot JW,et al.Current concepts in RET-related genetics,signaling and therapeutics[J].Trends Genet,2006,22(11):627-636.
7 Iwashita T,Kato M,Murakami H,et al.Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma[J].Oncogene,1999,18(26):3919-3922.
8 唐波,姜军.RET/PTC3基因重排在甲状腺癌中的作用机制及研究进展[J].中华实验外科杂志,2013,30(10):2241-2242.
9 苗素生,孙冀,裴荣.RET和VEGF-C在甲状腺乳头状癌中表达的研究[J].实用肿瘤学杂志,2010,(24)4:373-377.
10 Esseghir S,Todd SK,Hunt T,et al,A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer[J].Cancer Res,2007,67(24):11732-11741.
11 Borrello MG,Alberti L,Arighi E,et al.The full oncogenic activity of Ret/ptc2 depends on tyrosine 539,a Docking site for phospholipase C gamma[J].Mol Cell Biol,1996,16(5):2151-2163.
12 Kang J,Qian PX,Pandey V,et al.Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma[J].Oncogene,2010,29(22):3228-3240.
13 Spanheimer PM,Cyr AR,Gillum MP,et al.Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy[J].Ann Surg,2014,259(4):793-799.
14 Gattelli A,Nalvarte I,Boulay A,et al.Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells[J].Embo Mol Med,2013,5(9):1335-1350.
15 Ju YS,Lee WC,Shin JY,et al.A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing[J].Genome Res,2012,22(3):436-445.
16 Kohno T,Ichikawa H,Totoki Y,et al.KIF5B-RET fusions in lung adenocarcinoma[J].Nat Med,2012,18(10):375-377.
17 Lipson D,Capelletti M,Yelensky R,et al.Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies[J].Nat Med,2012,18(3):382-384.
18 Drilon A,Wang L,Hasanovic A,et al.Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas[J].Cancer Discov,2013,3(6):630-635.
19 Gainor JF,Shaw AT.The new kid on the block:RET in lung cancer[J].Cancer Discov,2013,3(6):604-606.
20 Gainor JF,Shaw AT.Novel targets in non-small cell lung cancer:ROS1 and RET fusions[J].Oncologist,2013,18(7):865-875.
21 Wedge SR,Ogilvie DJ,Dukes M,et al.ZD6474 inhibits vascular endothelial growth factor signaling,angiogenesis,and tumor growth following oral administration[J].Cancer Res,2002,62(16):4645-4655.
22 Wells Jr SA,Robinson BG,Gagel RF,et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized,double-blind phase III trial[J].J Clin Oncol,2012,30(2):134-141.

[1]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[2]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[3]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[4]	刘志强,褚艳杰,刘静,王彦博. m白术内酯Ⅰ通过TLR4/MyD88通路调控肺癌A549细胞增殖侵袭的研究[J]. 实用肿瘤学杂志, 2019, 33(3): 228-232.
[5]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[6]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[7]	张彦秋,韩阿蒙,李金旺,顾涛,付占昭,毛羽,张子健,杨振. CRT+ARC技术在局部晚期肺癌患者中临床应用的初步研究[J]. 实用肿瘤学杂志, 2019, 33(3): 256-260.
[8]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[9]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[10]	赵苏, 郑晓瑜, 朱开彬, 卜建龙, 徐世东. 肺癌完全性切除术对患者外周血中Th17/Treg细胞平衡的影响[J]. 实用肿瘤学杂志, 2019, 33(2): 142-148.
[11]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[12]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[13]	胡智慧综述, 张静审校. SNP对放射性肺损伤预测作用的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 87-91.
[14]	迪娜·木拉力, 胡昕综述, 加孜那·托哈依审校. 远程医疗在肺癌中的应用及前景[J]. 实用肿瘤学杂志, 2018, 32(6): 555-557.
[15]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.

RET基因在肿瘤中的研究现状和展望

Research of RET in cancer:Current and future

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价